VIPoma other imaging findings

VIPoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating VIPoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
VIPoma other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of VIPoma other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on VIPoma other imaging findings
CDC on VIPoma other imaging findings
VIPoma other imaging findings in the news
Blogs on VIPoma other imaging findings
Directions to Hospitals Treating VIPoma
Risk calculators and risk factors for VIPoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan.

Other Imaging Findings

Somatostatin receptor scintigraphy is used to localise the tumor, which is usually metastatic at presentation.

• 
  PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image).

References

Template:WikiDoc Sources